J&J shares rise on Caplyta bipolar mania endpoint result
Johnson & Johnson shares gained about 0.8% to $272.34 Monday after Caplyta hit its primary endpoint in a late-stage bipolar mania study, prompting investors to weigh potential expansion.
Johnson & Johnson said Caplyta hit its primary endpoint in a late-stage bipolar mania study, giving the drug another potential growth path. 34 Monday as investors weighed the result.